|
Abstract:
The main goal of this proposal is to study the anti-tumor activity of p2O2 and its application in a breast cancer model system. Three specific aims are: 1) To determine the effects of p202 on the sensitivity of breast cancer cells to anticancer agents; 2) To test the anti-tumor activity of p202 in breast cancer cells using preclinical gene therapy strategies in an orthotopic breast cancer animal model; and 3) To evaluate the therapeutic efficacy of p202 gene therapy in combination with other anti-cancer agents in an orthotopic breast cancer animal model. We have developed a p202-based therapeutic agent to study its efficacy in animal models in the first year of grant supported period. Our results have shown that adenovirus-mediated p202 gene transfer and its expression can cause growth-suppression and sensitization to TNF-alpha, taxol, CDDP and gamma-irradiation induced apoptosis of breast cancer cells. In the last year, we have completed CMV-p202-liposome delivery system in vivo via intratumoral and i.v. injection, and immunohistostaining in p202-treated breast cancer cells.
| Limitations: |
 APPROVED FOR PUBLIC RELEASE |
| Description: |
Annual rept. 1 Apr 2001-31 Mar 2002 |
| Pages: |
39 |
| Report Date: |
APR 2002 |
| Contract Number: |
DAMD17-00-1-0312 |
| Report Number: |
A208404 |
|
|
|
|
|
Keywords relating to this report:
Email This Abstract
